ArticleHuman vaccines & immunotherapeutics2025
Research hotspots and trends in lung cancer immunotherapy are revealed by a bibliometric study spanning the years 2004 to 2024.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Bibliometric analysis on the correlation between colorectal cancer and tumor microenvironment [2009-2024].Journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To summarize the research status of lung cancer immunotherapy using bibliometrics. CiteSpace software was used to analyze all literature on lung cancer immunotherapy collected from the Web of Science (WOS) database from 2004 to 2024. A total of 1702 publications on lung cancer immunotherapy were searched, and the number of articles increased more rapidly after 2014. Two areas intensively studied by the discipline are tumor microenvironment and dendritic cells. He, Jie, Chinese Academy of Medical Sciences - Peking Union Medical College, and China of America were the authors, institutions, and countries with the most. The research trajectory in the use of immunotherapy for lung cancer is thoroughly examined in this article. With tumor microenvironment, blockade, nivolumab, resistance, and chemotherapy being the primary research hotspots. Future studies might concentrate on melanoma, antibody, dendritic cells, non-small cell lung cancer, and ctla 4 blockade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.